Teva Pharmaceutical Industries, the world’s largest generic drug maker, based in Israel, unveiled its restructuring plan yesterday, which comes with big cuts to its research and development (R&D) department and staff.
Teva Pharmaceutical Industries, the world’s largest generic drug maker, based in Israel, unveiled its restructuring plan yesterday, which comes with big cuts to its research and development (R&D) department and staff.
President and CEO Kare Schultz said in a letter, “The plan will address a number of key areas, including the closure or divestment of a significant number of R&D facilities, headquarters, and office locations across all geographies.”
The plan is said to lead to 14,000 layoffs beginning in 2018, which accounts for about 25% of Teva’s total workforce. The company plans to begin notifying affected employees over the next 3 months. Schultz said that “all business and regions will be affected.” In addition to the layoffs, Teva plans to suspend its dividend on ordinary shares.
Shares in Teva were up 14.6% on news of the plan, though its shares overall are down 53% since January.
The 2-year restructuring plan aims to cut Teva’s costs by $3 billion by the end of 2019, from an estimated base of $16.1 billion, according to Fierce Biotech. However, the restructuring itself will end up costing the company at least $700 million in 2018, mainly related to severance costs, according to a statement.
“We will execute this plan in a timely and prudent manner, remaining focused on revenue and cash flow generation, in order to make sure Teva is ready to meet all of its financial commitments,” said Schultz in the letter.
Reuters reports that Teva needed to make a change in order to stay afloat, as it was saddled with about $35 billion of debt after acquiring Allergan’s Actavis generic drug business for $40.5 billion.
The company also expects to receive help next year from 2 new branded products — its migraine drug fremanezumab and austedo, which treats abnormal, involuntary movements associated with Huntington’s disease. Teva is also partnered with Celltrion in the development of 2 biosimilars: CT-P10, a proposed rituximab biosimilar, and CT-P6, a proposed trastuzumab biosimilars.
Teva is expected to provide its 2018 outlook in February, and will give a longer-term strategic plan for the company later that year.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.